4685-50-1

Usage

Uses

Used in Fragrance Industry:
Benzenemethanol, 3-methoxy-4-methylis used as a fragrance ingredient in perfumes and cosmetics for its sweet, floral scent, enhancing the overall aroma of these products.
Used in Pharmaceutical Industry:
Benzenemethanol, 3-methoxy-4-methylhas potential applications in the pharmaceutical industry, where it may be utilized in the development of new drugs or as an intermediate in the synthesis of existing medications.
Used in Organic Synthesis:
Benzenemethanol, 3-methoxy-4-methylis also used in organic synthesis, serving as a building block for the creation of more complex organic compounds.
It is important to handle this chemical with care, as it can be harmful if ingested or inhaled, and can cause skin and eye irritation.

Upstream product

• 57295-30-4 3-hydroxy-4-methylbenzaldehyde 
• 62454-72-2 4-methyl-3-sulfobenzoic acid 
• 586-30-1 3-hydroxy-4-methylbenzoic acid 
• 104901-43-1 methyl 3-bromo-4-methylbenzoate 
• 7697-26-9 3-bromo-4-methylbenzoic acid 
• 24973-22-6 3-methoxy-4-methylbenzaldehyde 
• 3556-83-0 methyl 4-methyl-3-methoxybenzoate 

Downstream Products

• 64829-31-8 2-(3-methoxy-4-methylphenyl)acetonitrile 
• 24973-22-6 3-methoxy-4-methylbenzaldehyde 
• 122488-92-0 3-methoxy-4-methylbenzyl bromide 
• 4685-61-4 C₂₀H₁₈N₂O₂ 
• 4685-58-9 2-Hydroxy-3,6,8-trimethyl-benzocyclohepten-7-one 
• 4685-52-3 1,2-Bis-chloromethyl-4-methoxy-5-methyl-benzene 
• 90296-17-6 (3-Methoxy-4-methyl-benzyloxy)-acetic acid 
• 501371-37-5 2-methoxy-1-methyl-4-vinylbenzene 
• 122334-01-4 ethyl 4-(3-methoxy-4-methylphenyl)butanoate 
• 4685-51-2 4-(chloromethyl)-2-methoxy-1-methylbenzene 
• 1392422-13-7 (4-chlorophenyl)(3-methoxy-4-(pyrrolidin-1-ylmethyl)phenyl)methanamine 
• 1392422-09-1 (4-chlorophenyl)(3-methoxy-4-(pyrrolidin-1-ylmethyl)phenyl)methanone 
• 1096987-59-5 (4-chlorophenyl)(3-methoxy-4-methylphenyl)methanone 

Relevant academic research and scientific papers

Synthesis of Functionalized Indolines and Dihydrobenzofurans by Iron and Copper Catalyzed Aryl C-N and C-O Bond Formation

A simple and effective one-pot, two-step intramolecular aryl C-N and C-O bond forming process for the preparation of a wide range of benzo-fused heterocyclic scaffolds using iron and copper catalysis is described. Activated aryl rings were subjected to a highly regioselective, iron(III) triflimide-catalyzed iodination, followed by a copper(I)-catalyzed intramolecular N-or O-arylation step leading to indolines, dihydrobenzofurans, and six-membered analogues. The general applicability and functional group tolerance of this method were exemplified by the total synthesis of the neolignan natural product, (+)-obtusafuran. DFT calculations using Fukui functions were also performed, providing a molecular orbital rationale for the highly regioselective arene iodination process.

Discovery of a 1-Methyl-3,4-dihydronaphthalene-Based Sphingosine-1-Phosphate (S1P) Receptor Agonist Ceralifimod (ONO-4641). A S1P1 and S1P5 Selective Agonist for the Treatment of Autoimmune Diseases

The discovery of 1-({6-[(2-methoxy-4-propylbenzyl)oxy]-1-methyl-3,4-dihydronaphthalen-2-yl}methyl)azetidine-3-carboxylic acid 13n (ceralifimod, ONO-4641), a sphingosine-1-phosphate (S1P) receptor agonist selective for S1P1 and S1P5, is described. While it has been revealed that the modulation of the S1P1 receptor is an effective way to treat autoimmune diseases such as relapsing-remitting multiple sclerosis (RRMS), it was also reported that activation of the S1P3 receptor is implicated in some undesirable effects. We carried out a structure-activity relationship (SAR) study of hit compound 6 with an amino acid moiety in the hydrophilic head region. Following identification of a lead compound with a dihydronaphthalene central core by inducing conformational constraint, optimization of the lipophilic tail region led to the discovery of 13n as a clinical candidate that exhibited >30 000-fold selectivity for S1P1 over S1P3 and was potent in a peripheral lymphocyte lowering (PLL) test in mice (ED50 = 0.029 mg/kg, 24 h after oral dosing).

A novel anti-Alzheimer agent inhibiting oligomerization and fibriliation of beta-amyloid protects neuronal cell from Aβ-induced cytotoxicity

The present invention relates to development of a novel treatment agent for Alzheimerandprime;s disease, having ability of protecting neural cells and inhibiting fibrosis and oligomerization of beta-amyloid. A compound of the present invention is capable of, while maintaining therapeutic effects on Alzheimerandprime;s disease, recovering ability of directly inhibiting oligomerized and fibrous amyloid beta, which is inherent activities of existing curcumin, thereby being useful as a novel inhibitor.COPYRIGHT KIPO 2017

Dicyanovinyl-substituted J147 analogue inhibits oligomerization and fibrillation of β-amyloid peptides and protects neuronal cells from β-amyloid-induced cytotoxicity

A series of novel J147 derivatives were synthesized, and their inhibitory activities against β-amyloid (Aβ) aggregation and toxicity were evaluated by using the oligomer-specific antibody assay, the thioflavin-T fluorescence assay, and a cell viability assay in the transformed SH-SY5Y cell culture. Among the synthesized J147 derivatives, 3j with a 2,2-dicyanovinyl substituent showed the most potent inhibitory activity against Aβ42 oligomerization (IC50 = 17.3 μM) and Aβ42 fibrillization (IC50 = 10.5 μM), and disassembled the preformed Aβ42 fibrils with an EC50 of 10.2 μM. Finally, we confirmed that 3j is also effective at preventing neurotoxicity induced by Aβ42-oligomers as well as Aβ42-fibrils.

Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: Further structure-activity relationships, in vivo studies, and preliminary toxicity profiling

Despite recent progress in the fight against malaria, the emergence and spread of drug-resistant parasites remains a serious obstacle to the treatment of infections. We recently reported the development of a novel antimalarial drug that combines the 4-aminoquinoline pharmacophore of chloroquine with that of clotrimazole-based antimalarials. Here we describe the optimization of this class of hybrid drug through in-depth structure-activity relationship studies. Antiplasmodial properties and mode of action were characterized in vitro and in vivo, and interactions with the parasites 'chloroquine resistance transporter' were investigated in a Xenopus laevis oocyte expression system. These tests indicated that piperazine derivatives 4b and 4d may be suitable for coadministration with chloroquine against chloroquine-resistant parasites. The potential for metabolism of the drugs by cytochrome P450 was determined in silico, and the lead compounds were tested for toxicity and mutagenicity. A preliminary pharmacokinetic analysis undertaken in mice indicated that compound 4b has an optimal half-life.

COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF

The present invention provides novel beta-secretase inhibitors of the general formula (I), where the variables A1, A2, L1, L2, L3, R1, R2, R3, R4, R5, R6 and R7 are as defined in the claims, a method for their use in treating Alzheimer's disease, and methods for their use in reducing memapsin 2 catalytic activity.

Stereoselective syntheses of (±)-komaroviquinone and (±)-faveline methyl ether through intramolecular Heck reaction

An efficient, flexible, and stereoselective convergent route for constructing the trans-10-hydroxy-1,1-dimethyloctahydrodibenzo[a,d]cyclohepten- 7-ones (5a-c) was achieved via intramolecular Heck reaction. This strategy has been successfully implemented for the syntheses of (±)-komaroviquinone (3) through (±)-coulterone dimethyl ether (5c) and (±)-faveline methyl ether (1a).

Baker's yeast-mediated enantioselective synthesis of the bisabolane sesquiterpenes (+)-curcuphenol, (+)-xanthorrhizol, (-)-curcuquinone and (+)-curcuhydroquinone

Fermenting baker's yeast converts the unsaturated aldehydes 5a-c into the saturated alcohols 6a-c, respectively. The microbial saturation of substrates adsorbed on a nonpolar resin proceeds in high chemical yields and shows complete enantioselectivity in the formation of the (S)-(+) isomers. Enantiopure 6a-c are versatile chiral building blocks for the synthesis of bisabolane sesquiterpenes. Their usefulness is shown in the preparation of (S)-(+)-curcuphenol, (S)-(+)-xanthorrhizol, (S)-(-)-curcuquinone and (S)-(+)-curcuhydroquinone. The Royal Society of Chemistry 2000.

Highly efficient conversion of benzoates to alcohols with sodium borohydride in DME-MeOH

Methoxybenzoates were quantitatively reduced to the corresponding alcohols with sodium borohydride in a mixed solvent (DME-MeOH). The described method was applicable to a large scale synthesis.